Mutational spectrum of p53 mutations in primary breast and ovarian tumors

被引:108
作者
Feki, A
Irminger-Finger, I
机构
[1] Univ Geneva, Biol Aging Lab, Dept Geriatr, CH-1225 Geneva, Switzerland
[2] Univ Geneva, Monitoring Lab, Dept Geriatr, CH-1225 Geneva, Switzerland
[3] Univ Hosp Geneva, Dept Gynecol & Obstet, CH-1225 Geneva, Switzerland
关键词
apoptosis; breast cancer; chemosensitivity; ovarian cancer; p53; prognostic marker;
D O I
10.1016/j.critrevonc.2004.07.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast and ovarian cancers, like other cancers, occur due to genetic damage. Research aimed to determine the specific genes involved in the development of breast and ovarian cancers will help to understand how normal breast and ovarian epithelial cells escape regulation of proliferation, apoptosis and senescence. It was determined that approximately 10% of ovarian cancers and 20-30% of breast cancers arise in women who have inherited mutations in cancer susceptibility genes such as BRCA1, BRCA2 and other DNA repair genes. The ability to perform genetic testing permits the identification of women at increased risk who can then be offered preventive strategies. The vast majority of ovarian and breast cancers are sporadic, presumably resulting from the accumulation of genetic damage over lifetime. Several genes involved in breast and ovarian carcinogenesis have been identified, most notably the p53 tumor suppressor. The recent availability of expression microarrays has facilitated the simultaneous screening of thousands of genes and this will extend further the understanding of molecular events involved in the dynamic development of ovarian and breast cancers. Then, all this knowledge could be translated into effective screening, surveillance, prevention, and treatment strategies in the future. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:103 / 116
页数:14
相关论文
共 143 条
[1]   The significance of p53 mutation and over-expression in ovarian cancer prognosis [J].
Allan, LA ;
Campbell, MK ;
Milner, BJ ;
Eccles, DM ;
Leonard, RCF ;
Parkin, DE ;
Miller, ID ;
Lessells, AM ;
Kitchener, HC ;
Haites, NE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (06) :483-490
[2]  
Allred D C, 1994, Cancer Treat Res, V71, P63
[3]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[4]  
Alsner J, 2000, CLIN CANCER RES, V6, P3923
[5]   TOO MANY RODENT CARCINOGENS - MITOGENESIS INCREASES MUTAGENESIS [J].
AMES, BN ;
GOLD, LS .
SCIENCE, 1990, 249 (4972) :970-971
[6]   PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA [J].
ANDERSEN, TI ;
HOLM, R ;
NESLAND, JM ;
HEIMDAL, KR ;
OTTESTAD, L ;
BORRESEN, AL .
BRITISH JOURNAL OF CANCER, 1993, 68 (03) :540-548
[7]   Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer [J].
Baekelandt, M ;
Kristensen, GB ;
Nesland, JM ;
Tropé, CG ;
Holm, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2061-2068
[8]  
BAKER SJ, 1990, CANCER RES, V50, P7717
[9]   IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN MAMMARY-CARCINOMA - AN IMPORTANT NEW INDEPENDENT INDICATOR OF PROGNOSIS [J].
BARNES, DM ;
DUBLIN, EA ;
FISHER, CJ ;
LEVISON, DA ;
MILLIS, RR .
HUMAN PATHOLOGY, 1993, 24 (05) :469-476
[10]   Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53 [J].
Beenken, SW ;
Grizzle, WE ;
Crowe, DR ;
Conner, MG ;
Weiss, HL ;
Sellers, MT ;
Krontiras, H ;
Urist, MM ;
Bland, KI .
ANNALS OF SURGERY, 2001, 233 (05) :630-637